UPDATE: Wunderlich Initiates Coverage on DexCom at Buy
According to Wunderlich Securities, DexCom (NASDAQ: DXCM) coverage is initiated at Buy.
Wunderlich Securities said that it is initiating coverage of DexCom, Inc. (DXCM) with a Buy rating and $12 target. “We believe growing visibility on the Gen4 approval process will allow DXCM shares to reach, and possibly exceed, our $12 price target over the next 12 months.”
DexCom closed yesterday at $8.54.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.